AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1500630 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut immunotherapy
Number of subjects: 4
Study 1500630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 6869487 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger spreader
Number of subjects: 12
Study 6869487 — intervention group
Group type: COMPARATOR
Intervention: Volar resting splint
Number of subjects: 12
Study 6869487 — intervention group
Group type: COMPARATOR
Intervention: No device
Number of subjects: 12
Study 6869487 — intervention group
Group type: COMPARATOR
Intervention: Firm cone
Number of subjects: 12
Study 31881986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified bread with 500 IU/100 g
Number of subjects: 90
Study 31881986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified bread with 1000 IU/100 g
Number of subjects: 90
Study 31881986 — intervention group
Group type: COMPARATOR
Intervention: Plain bread (control group)
Number of subjects: 90
Study 29376774 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Continuous Exercise (HICE)
Number of subjects: 12
Study 29376774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Volume High-Intensity Interval Exercise (HIIE)
Number of subjects: 12
Study 29376774 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE)
Number of subjects: 12
Study 26764332 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged Garlic Extract (AGE) 2.56 g/d for 90 days
Number of subjects: 120
Study 26764332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 24912844 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Programme (HeLP)
Number of subjects: 201
Study 22186135 — intervention group
Group type: EXPERIMENTAL
Intervention: TORCH (Treatment of Resistant Command Hallucinations)
Number of subjects: 43
Study 22186135 — intervention group
Group type: COMPARATOR
Intervention: Befriending
Number of subjects: 43
Study 22186135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatments
Number of subjects: 43
Study 22186135 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 43
Study 21293762 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 94
Study 21293762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 18065582 — intervention group
Group type: EXPERIMENTAL
Intervention: Atwater factors and related food energy conversion factors
Number of subjects: 27
Study 18065582 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Atwater factors
Number of subjects: 27
Study 18065582 — intervention group
Group type: EXPERIMENTAL
Intervention: Various factorial and empirical systems for calculating food energy
Number of subjects: 27
Study 16237776 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative parenteral nutrition
Number of subjects: 32
Study 16237776 — intervention group
Group type: COMPARATOR
Intervention: Control (no parenteral nutrition)
Number of subjects: 32
Study 12401582 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7% halothane
Number of subjects: 20
Study 12401582 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% isoflurane
Number of subjects: 20
Study 12401582 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 micro g/kg IV fentanyl
Number of subjects: 20
Study 12401582 — intervention group
Group type: COMPARATOR
Intervention: 1.5% lidocaine plus 0.35 mg/kg IV propofol
Number of subjects: 20
Study 10343983 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7998062 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration of apheresis platelets
Number of subjects: 0
Study 7998062 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration of pooled platelets
Number of subjects: 0
Study 7998062 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration of CPDA-1 packed red cells
Number of subjects: 0
Study 7998062 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration of Adsol packed red cells
Number of subjects: 0
Study 2281802 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright morning light (0600 to 0800)
Number of subjects: 7
Study 2281802 — intervention group
Group type: COMPARATOR
Intervention: Bright evening light (2000 to 2200)
Number of subjects: 7
Study 6809796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy group
Number of subjects: 44
Study 6809796 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional process-oriented interpersonal group
Number of subjects: 44
Study 6809796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy in an individual format
Number of subjects: 44
Study 31355514 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-Purified Protein Derivative (PPD)
Number of subjects: 45
Study 31355514 — intervention group
Group type: COMPARATOR
Intervention: IL-Vitamin D3
Number of subjects: 45
Study 30081960 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min interactive session discussing STI and HIV education, risk mitigation, and effective partner notification strategies.
Number of subjects: 30
Study 26814246 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 26814246 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose (0.375% ropivacaine, perineural additives)
Number of subjects: 80
Study 26814246 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Dose (0.2% ropivacaine, perineural additives)
Number of subjects: 80
Study 26814246 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose (0.1% ropivacaine, perineural additives)
Number of subjects: 80
Study 26814246 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose
Number of subjects: 80
Study 26814246 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose
Number of subjects: 80
Study 25043834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid plus pre-existing trainings
Number of subjects: 2543
Study 25043834 — intervention group
Group type: COMPARATOR
Intervention: Pre-existing trainings only
Number of subjects: 2543
Study 22242932 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2290
Study 19057896 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% nitrous oxide inhalation
Number of subjects: 30
Study 19057896 — intervention group
Group type: COMPARATOR
Intervention: Air plus oxygen inhalation (control)
Number of subjects: 30
Study 17463391 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute one-on-one HIV/STD behavioral skill-building intervention
Number of subjects: 564
Study 17463391 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-minute group HIV/STD behavioral skill-building intervention
Number of subjects: 564
Study 17463391 — intervention group
Group type: COMPARATOR
Intervention: 200-minute health intervention control group
Number of subjects: 564
Study 16860171 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/d olanzapine for 20 days (group A, n=12)
Number of subjects: 37
Study 16860171 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d for 10 days followed by 40 mg/d for 10 days (group B, n=11)
Number of subjects: 37
Study 16860171 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/d for 20 days (group C, n=14)
Number of subjects: 37
Study 14680736 — intervention group
Group type: EXPERIMENTAL
Intervention: Active (univentricular) pacing in long QRS group
Number of subjects: 86
Study 14680736 — intervention group
Group type: COMPARATOR
Intervention: Inactive (ventricular inhibited) pacing in short QRS group
Number of subjects: 86
Study 11013281 — intervention group
Group type: EXPERIMENTAL
Intervention: Teniposide with WBRT (10 fractions of 3 Gy)
Number of subjects: 120
Study 11013281 — intervention group
Group type: COMPARATOR
Intervention: Teniposide alone
Number of subjects: 120
Study 8840346 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone 10 mg
Number of subjects: 34
Study 8840346 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone 20 mg
Number of subjects: 34
Study 8840346 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 1735848 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (Exosurf Neonatal)
Number of subjects: 23
Study 1735848 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 23
Study 6547988 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg cimetidine daily
Number of subjects: 24
Study 6547988 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pirenzepine daily
Number of subjects: 24
Study 6547988 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with cimetidine and pirenzepine (800 mg cimetidine and 100 mg pirenzepine daily)
Number of subjects: 24
Study 6547988 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-treatment levels)
Number of subjects: 24
Study 6547988 — intervention group
Group type: COMPARATOR
Intervention: Control (serum calcium and phosphate levels)
Number of subjects: 24
Study 6547988 — intervention group
Group type: COMPARATOR
Intervention: Control (alkaline phosphatase activity)
Number of subjects: 24
Study 30930051 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training performed twice a week for 10 weeks
Number of subjects: 16
Study 30930051 — intervention group
Group type: COMPARATOR
Intervention: Control group continued their usual activities
Number of subjects: 16
Study 30480666 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of co-occurrence frequencies via relative frequency analysis and observed-expected frequency ratio
Number of subjects: 5364781
Study 30480666 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR prevalences
Number of subjects: 5364781
Study 28728767 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal artery thermometer (TAT)
Number of subjects: 298
Study 28728767 — intervention group
Group type: COMPARATOR
Intervention: Oral thermometer
Number of subjects: 298
Study 28728767 — intervention group
Group type: COMPARATOR
Intervention: Axillary thermometer
Number of subjects: 298
Study 26708233 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained resident coaches
Number of subjects: 14
Study 26708233 — intervention group
Group type: COMPARATOR
Intervention: Untrained resident coaches
Number of subjects: 14
Study 26708233 — intervention group
Group type: EXPERIMENTAL
Intervention: All students
Number of subjects: 14
Study 24506405 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet with antioxidant supplementation
Number of subjects: 9
Study 24506405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low-fat diet)
Number of subjects: 9
Study 21925636 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic midurethral sling
Number of subjects: 597
Study 21925636 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator midurethral sling
Number of subjects: 597
Study 21925636 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 597
Study 18434976 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (200 microg once daily)
Number of subjects: 983
Study 18434976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 983
Study 18434976 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Number of subjects: 983
Study 16177585 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based educational intervention using cellular phone and Internet for blood glucose monitoring
Number of subjects: 42
Study 13678870 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (target dose 32 mg once daily)
Number of subjects: 2028
Study 13678870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2028
Study 13678870 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2028
Study 13678870 — intervention group
Group type: COMPARATOR
Intervention: Candesartan and Placebo
Number of subjects: 2028
Study 10809018 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART plus rIL-2
Number of subjects: 14
Study 10809018 — intervention group
Group type: COMPARATOR
Intervention: HAART
Number of subjects: 14
Study 9010562 — intervention group
Group type: EXPERIMENTAL
Intervention: specific hyposensitization
Number of subjects: 20
Study 9010562 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 1900443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 35
Study 1900443 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 35
Study 6221388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone (16 micrograms/ml)
Number of subjects: 120
Study 6221388 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole (16 micrograms/ml) and/or Tobramycin (4 micrograms/ml)
Number of subjects: 120
Study 6221388 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole-tobramycin
Number of subjects: 120
Study 6221388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 120
Study 31277180 — intervention group
Group type: EXPERIMENTAL
Intervention: M-DEPTH (evidence-based stepped care treatment model)
Number of subjects: 400
Study 31277180 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 31277180 — intervention group
Group type: EXPERIMENTAL
Intervention: M-DEPTH
Number of subjects: 400
Study 29216730 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapeutic methods aimed at the temporomandibular joint
Number of subjects: 98
Study 29216730 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy aimed at cervical muscles only
Number of subjects: 98
Study 29216730 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex rehabilitation (combination of relaxing and stretching exercises of cervical muscles with standard therapy for masticatory muscles)
Number of subjects: 98
Study 25738784 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced protein intake (BAL: 25% daily protein/meal × 4)
Number of subjects: 20
Study 25738784 — intervention group
Group type: COMPARATOR
Intervention: Skewed protein intake (SKEW: 7:17:72:4% daily protein/meal)
Number of subjects: 20
Study 25076235 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser resection (group A)
Number of subjects: 72
Study 25076235 — intervention group
Group type: COMPARATOR
Intervention: Mechanical staplers with or without sealants (group B)
Number of subjects: 72
Study 22071248 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 39129
Study 22071248 — intervention group
Group type: COMPARATOR
Intervention: Control group (not vaccinated)
Number of subjects: 39129
Study 19620325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine (SDOX) 1,500 mg plus pyrimethamine (PYR) 75 mg
Number of subjects: 60
Study 17530985 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-set strength training (n = 22)
Number of subjects: 39
Study 17530985 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-set strength training (n = 22)
Number of subjects: 39
Study 17530985 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 39
Study 15231376 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol 50 mg
Number of subjects: 23144
Study 15231376 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene 20 mg
Number of subjects: 23144
Study 15231376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23144
Study 11199705 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser with an energy of 140 mJ, a pulse repetition rate of 4 Hz (no water cooling)
Number of subjects: 18
Study 11199705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAP laser with an energy of 240 mJ, a pulse repetition rate of 10 Hz (no water cooling)
Number of subjects: 18
Study 11199705 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed dental handpiece (no water cooling)
Number of subjects: 18
Study 11199705 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser with an energy of 140 mJ, a pulse repetition rate of 4 Hz (with water spray)
Number of subjects: 18
Study 11199705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAP laser with an energy of 240 mJ, a pulse repetition rate of 10 Hz (with water spray)
Number of subjects: 18
Study 11199705 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed dental handpiece (with water spray)
Number of subjects: 18
Study 9049526 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaprilat (5 ml or 10 ml injection twice daily)
Number of subjects: 0
Study 9049526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9049526 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaprilat
Number of subjects: 0
Study 8443480 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding the infant 20 cm below the introitus for 30 seconds before clamping the umbilical cord (regulated group, 17 patients)
Number of subjects: 36
Study 8443480 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (random group, 19 patients)
Number of subjects: 36
Study 8443480 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding the infant 20 cm below the introitus for 30 seconds before clamping the umbilical cord (regulated group)
Number of subjects: 36
Study 8443480 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (random group)
Number of subjects: 36
Study 3533563 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ICI 141,292
Number of subjects: 12
Study 3533563 — intervention group
Group type: COMPARATOR
Intervention: 100 mg atenolol
Number of subjects: 12
Study 3533563 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 141,292 and atenolol
Number of subjects: 12
Study 30844541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive transitional care by a nurse‐led multidisciplinary team (MDT)
Number of subjects: 0
Study 30844541 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 0
Study 28253390 — intervention group
Group type: EXPERIMENTAL
Intervention: TX+CEX (docetaxel plus capecitabine followed by cyclophosphamide, epirubicin, and capecitabine)
Number of subjects: 1495
Study 28253390 — intervention group
Group type: COMPARATOR
Intervention: T+CEF (docetaxel followed by cyclophosphamide, epirubicin, and fluorouracil)
Number of subjects: 1495
Study 25338110 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous titanium construct cup (n=25)
Number of subjects: 51
Study 25338110 — intervention group
Group type: COMPARATOR
Intervention: Conventional porous coated titanium cup (control group, n=26)
Number of subjects: 51
Study 24482090 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric
Number of subjects: 100
Study 24482090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21067273 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LP: 20 mL of 0.25% levobupivacaine infiltration to the nephrostomy tract followed by intravenous paracetamol infusion
Number of subjects: 60
Study 21067273 — intervention group
Group type: COMPARATOR
Intervention: Group SP: 20 mL saline infiltrated through the nephrostomy tract followed by intravenous paracetamol (4 × 1 g) infusion
Number of subjects: 60
Study 21067273 — intervention group
Group type: COMPARATOR
Intervention: Group LS: 20 mL of 0.25% levobupivacaine infiltration to the nephrostomy tract followed by intravenous saline infusion
Number of subjects: 60
Study 19910810 — intervention group
Group type: EXPERIMENTAL
Intervention: Basketball training (4-year systematic exercise program)
Number of subjects: 24
Study 19910810 — intervention group
Group type: COMPARATOR
Intervention: Occasional basketball participation (recreational)
Number of subjects: 24
Study 17300593 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg q.d. + Pioglitazone 30 mg q.d. (100/30 mg q.d.)
Number of subjects: 607
Study 17300593 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg q.d. + Pioglitazone 30 mg q.d. (50/15 mg q.d.)
Number of subjects: 607
Study 17300593 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 30 mg q.d. (monotherapy)
Number of subjects: 607
Study 17300593 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg q.d. (monotherapy)
Number of subjects: 607
Study 15215794 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 141
Study 15215794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 11149474 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 10 mg alendronate on alternate days for 2 years
Number of subjects: 26
Study 11149474 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 26
Study 11149474 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 10 mg alendronate
Number of subjects: 26
Study 10401948 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) in low ventilation group (10 l/min)
Number of subjects: 10
Study 10401948 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Tube Compensation (ATC) in low ventilation group (10 l/min)
Number of subjects: 10
Study 10401948 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Pressure Support (IPS) > 5 cm H2O in low ventilation group (10 l/min)
Number of subjects: 10
Study 10401948 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) in high ventilation group (> 10 l/min)
Number of subjects: 10
Study 10401948 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Tube Compensation (ATC) in high ventilation group (> 10 l/min)
Number of subjects: 10
Study 10401948 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory Pressure Support (IPS) in high ventilation group (> 10 l/min)
Number of subjects: 10
Study 8583073 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg bolus and 40 mg/12 h i.v.)
Number of subjects: 51
Study 8583073 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (50 mg/4 h i.v.)
Number of subjects: 51
Study 2193242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (Sandoglobulin, Sandoz) 400 mg/kg, two times with an interval of two weeks
Number of subjects: 10
Study 2193242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6996271 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 6996271 — intervention group
Group type: COMPARATOR
Intervention: Bell and pad conditioning method
Number of subjects: 0